Abstract：OBJECTIVE: To study the effects of treatment with gonadotropin-releasing hormone analogs (GnRHa) on final height, weight and pubertal development in girls with central precocious puberty. METHODS: Twenty-six girls with central precocious puberty were treated with GnRHa for an average of 19.2±8.4 months. Pretreatment and posttreatment predicted adult heights (PAH) were evaluated based on the Bayley-Pineau table. The patients' heights and weights were measured monthly. Bone age (BA) was evaluated using Greulich-Plyle. Height standard deviation score for BA ［HtSDS (BA)］ was measured. After discontinuation of treatment, the patients were followed-up for the observation of height, weight, BA and menstruation. RESULTS: Final height averaged 158.0±4.0 cm in the 26 girls, which was greater than their target height (155.3±4.4 cm; P<0.01) and consistent with their posttreatment PAH (158.4±5.2 cm). The final height was positively corrrelated with initial height, PAH and HtSDS(BA). There was a positive correlation in the body mass index before and after treatment (r=0.724, P<0.01). Menarche occurred 13.2±6.1 months after discontinuation of treatment, with a mean menarche age of 12.2±0.7 years. CONCLUSIONS: GnRHa may increase final height in girls with central precocious puberty. Their final heights may be correlated with their initial heights and PAH. The pubertal development after GnRHa treatment in girls with central precocious puberty may be matched with normal children.［Chin J Contemp Pediatr, 2009, 11 (5):374-376］
CHEN Shao-Ke,FAN Xin,TANG Qing. Impact of gonadotropin-releasing hormone analogs treatment on final height in girls with central precocious puberty[J]. CJCP, 2009, 11(05): 374-376.
［3］Pasquino AM, Pucarelli I, Roggini M, Segni M. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone［J］. J Clin Endocrinol Metab, 2000, 85(2):619-622.
［5］Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience［J］. J Clin Endocrinol Metab, 2001, 86(10):4711-4716.
［6］Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function［J］. J Clin Endocrinol Metab, 2008, 93(1):190-195.
［8］Viru A. Plasma hormones and physical exercise［J］. Int J Sports Med, 1992, 13（3）：201-209.
［9］Martín Díaz MJ, Soriano Guillén L, Muoz Calvo MT, Pozo Román J, Argente Oliver J.Triptorelin therapy in girls with central precocious puberty increases body mass index［J］. An Pediatr (Barc), 2006, 11,65(5):428-433.
［10］Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty［J］. J Clin Endocrinol Metab, 1999, 84(12):4480-4488.
［11］Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, et al. Reduction of baseline body mass index under gonadotropinsuppressive therapy in girls with idiopathic precocious puberty［J］. Eur J Endocrinol, 2004, 150(4):533-537.
［12］Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey［J］. BMJ, 2000, 320(7244):1240-1243.
